Rationale: Asympotamic syringomyelia accompanied with metastatic cerebellar and thoracic spinal intramedullary lymphoma is rare in clinical practice. If the intramedullary lymphoma is large enough, the patient will rapidly develop neurologic signs of spinal injury. The prognosis of this type of complication is always bad.
Patient Concerns: Rapid and correct diagnosis and treatment is important for metastatic extranodal lymphoma with B cell of origin.
Diagnoses: Syringomyelia accompanied with metastatic cerebellar and thoracic spinal intramedullary lymphoma.
Interventions: The patient was treated with a combination of systemic chemotherapy and focal radiotherapy and intrathecal therapy.
Outcomes: Resolution of metastatic lymphoma was not continued after conservative medical management and the patient died finally due to multiple organ failure.
Lessons: Syringomyelia can develop due to the metastatic thoracic intramedullary lymphoma in patients with diffuse malignant large B cell lymphoma. Early and accurate diagnosis, anti-lymphoma treatment, and timely neurosurgical intervention may delay the development of the disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704820 | PMC |
| http://dx.doi.org/10.1097/MD.0000000000008593 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary central nervous system lymphoma of the spinal cord: A LOC network cohort study.
Rev Neurol (Paris)
December 2024
Service de neuro-oncologie, hôpital Pitié-Salpêtrière, IHU, ICM, Sorbonne université, AP-HP, 72, boulevard de la Villette, 75019 Paris, France.
Purpose: Primary central nervous system lymphoma (PCNSL) mainly affects the brain (>90% cases); there are very little data pertaining to PCNSL involving the spinal cord.
Methods: We retrospectively selected from the French LOC network database adult immunocompetent patients diagnosed with PCNSL involving the spinal cord between 2011 and 2022.
Results: Of the 2043 patients records retrieved from the database, 16 patients (median age: 62.
Efficacy of Surgical Intervention in Treating Pathological Fractures of the Upper Extremity: A Retrospective Case Series.
Cureus
October 2024
Orthopedic Surgery, Kindai University Hospital, Osakasayama, JPN.
Background: We conduct a retrospective analysis of patients with pathological fractures resulting from upper extremity malignancies, focusing on the evaluation of treatment strategies employed.
Materials And Methods: We retrospectively studied 10 patients with metastatic bone tumors of the upper extremities. The study variables included tumor site, primary pathology, duration from the first diagnosis of the primary lesion to the occurrence of the pathological fracture, use of bone-modifying drugs, surgical technique, adjuvant therapy, postoperative functional assessment, Katagiri's score, American Society of Anesthesiologists physical status (ASA-PS), outcome, and correlations between the Eastern Cooperative Oncology Group Performance Status (ECOG-PS) and Musculoskeletal Tumor Society (MSTS) score.
[Primary intramedullary spinal cord lymphoma with long spinal cord lesion].
Rinsho Shinkeigaku
October 2024
Department of Neurology, Hyogo Prefectural Harima-Himeji General Medical Center.
Long-term survival following molecular-targeted therapy for intramedullary non-small-cell lung cancer metastasis.
Surg Neurol Int
August 2024
Spinal Disorders Center, Division of Neurosurgery, Shizuoka Cancer Center, Nagaizumi, Japan.
Background: Intramedullary spinal cord metastases (ICSMs) are very rarely curable; these patients typically have very short-term survival rates. Here, a 22-year-old male with non-small-cell lung cancer (NSCLC) later developed ICSM twice; the first C4-C7 tumor responded well to surgery, radiation, and alectinib molecular-targeted therapy. The secondary ICSM C1 lesion seen years later (i.
View Article and Find Full Text PDFChemotherapy Release From Bortezomib-Impregnated Polymethylmethacrylate-Coated Intramedullary Nails: A Novel In Vitro Study for a Local Chemotherapy Delivery Device.
Cureus
July 2024
Department of Orthopaedic Surgery, Wayne State University Detroit Medical Center, Detroit, USA.
Bortezomib (BAN) is a proteasome inhibitor approved for the treatment of multiple myeloma and lymphoma. Despite its efficacy in various tumor models, systemic administration can result in toxicity to healthy organs. The purpose of this study is to evaluate the elution profile of BAN from PMMA cement for the local treatment of orthopedic tumors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!